{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:55:12Z","timestamp":1793228112182,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01436-0","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T17:05:18Z","timestamp":1766855118000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma: results of the Phase 2 study IZALCO"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3148-7432","authenticated-orcid":false,"given":"Gurdeep","family":"Parmar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5224-1979","authenticated-orcid":false,"given":"Marcelo","family":"Capra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6637-3588","authenticated-orcid":false,"given":"Fernanda","family":"Seguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4327-1957","authenticated-orcid":false,"given":"Vania","family":"Hungria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios-Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sosana","family":"Delimpasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0513-326X","authenticated-orcid":false,"given":"Ji\u0159\u00ed","family":"Mina\u0159\u00edk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5451-5283","authenticated-orcid":false,"given":"Ivan","family":"\u0160pi\u010dka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lud\u011bk","family":"Pour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herlander","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gra\u00e7a","family":"Esteves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8229-7439","authenticated-orcid":false,"given":"Kazutaka","family":"Sunami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4908-1636","authenticated-orcid":false,"given":"Junichiro","family":"Yuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6955-6267","authenticated-orcid":false,"given":"Roman","family":"H\u00e1jek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Mih\u00e1lyov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Soufflet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Disa","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadija","family":"Benlhassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victorine","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Comerford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cordero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Suzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4796-3352","authenticated-orcid":false,"given":"Hang","family":"Quach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,27]]},"reference":[{"key":"1436_CR1","first-page":"e528","volume":"5","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Hemasphere. 2021;5:e528.","journal-title":"Hemasphere"},{"key":"1436_CR2","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines, multiple myeloma. Version 1. 2025. https:\/\/www.nccn.org."},{"key":"1436_CR3","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","volume":"397","author":"P Moreau","year":"2021","unstructured":"Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, et al. IKEMA study group. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397:2361\u201371.","journal-title":"Lancet"},{"key":"1436_CR4","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","volume":"391","author":"T Facon","year":"2024","unstructured":"Facon T, Dimopoulos MA, Leleu XP, Beksac M, Pour L, H\u00e1jek R, et al. IMROZ Study Group. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391:1597\u2013609.","journal-title":"N Engl J Med"},{"key":"1436_CR5","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1007\/s00277-022-04917-5","volume":"101","author":"X Leleu","year":"2022","unstructured":"Leleu X, Martin T, Weisel K, Schjesvold F, Iida S, Malavasi F, et al. Anti-CD38 antibody therapy for patients with relapsed\/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes. Ann Hematol. 2022;101:2123\u201337.","journal-title":"Ann Hematol"},{"key":"1436_CR6","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-14-0695","volume":"20","author":"J Deckert","year":"2014","unstructured":"Deckert J, Wetzel MC, Bartle LM, Skaletskaya A, Goldmacher VS, Vall\u00e9e F, et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res. 2014;20:4574\u201383.","journal-title":"Clin Cancer Res"},{"key":"1436_CR7","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.3389\/fimmu.2020.01771","volume":"11","author":"C Zhu","year":"2020","unstructured":"Zhu C, Zhu C, Song Z, Wang A, Srinivasan S, Yang G, et al. Isatuximab acts through Fc-dependent, independent, and direct pathways to kill multiple myeloma cells. Front Immunol. 2020;11:1771.","journal-title":"Front Immunol"},{"key":"1436_CR8","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1182\/blood.2021012448","volume":"139","author":"S Kassem","year":"2022","unstructured":"Kassem S, Diallo BK, El-Murr N, Carri\u00e9 N, Tang A, Fournier A, et al. SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma. Blood. 2022;139:1160\u201376.","journal-title":"Blood"},{"key":"1436_CR9","unstructured":"Sarclisa\u00ae (isatuximab-irfc) injection, for intravenous use. Prescribing Information. Sanofi-Aventis. U.S. LLC. 2024. https:\/\/products.sanofi.us\/Sarclisa\/sarclisa.pdf."},{"key":"1436_CR10","unstructured":"European Medicines Agency. Sarclisa EPAR\u2014Product information. Sanofi-Aventis. 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/sarclisa#product-info."},{"key":"1436_CR11","doi-asserted-by":"publisher","first-page":"e0261336","DOI":"10.1371\/journal.pone.0261336","volume":"17","author":"MJ Harvey","year":"2022","unstructured":"Harvey MJ, Zhong Y, Morris E, Beverage JN, Epstein RS, Chawla AJ. Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma. PLoS ONE. 2022;17:e0261336.","journal-title":"PLoS ONE"},{"key":"1436_CR12","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s12325-021-01996-0","volume":"39","author":"C Jackisch","year":"2022","unstructured":"Jackisch C, Manevy F, Frank S, Roberts N, Shafrin J. White paper on the value of time savings for patients and healthcare providers of breast cancer therapy: the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection as an example. Adv Ther. 2022;39:833\u201344.","journal-title":"Adv Ther"},{"key":"1436_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40259-023-00626-1","volume":"38","author":"B Bittner","year":"2024","unstructured":"Bittner B, Schmidt J. Advancing subcutaneous dosing regimens for biotherapeutics: clinical strategies for expedited market access. BioDrugs. 2024;38:23\u201346.","journal-title":"BioDrugs"},{"key":"1436_CR14","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S1470-2045(13)70383-8","volume":"14","author":"X Pivot","year":"2013","unstructured":"Pivot X, Gligorov J, M\u00fcller V, Barrett-Lee P, Verma S, Knoop A, et al. PrefHer Study Group. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 2013;14:962\u201370.","journal-title":"Lancet Oncol"},{"key":"1436_CR15","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.clml.2024.02.004","volume":"24","author":"H Quach","year":"2024","unstructured":"Quach H, Parmar G, Mateos MV, Ailawadhi S, Leleu X. Recent developments in convenience of administration of the anti-CD38 antibody isatuximab: subcutaneous delivery and fast intravenous infusion in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk. 2024;24:358\u201363.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1436_CR16","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.3324\/haematol.2023.284730","volume":"109","author":"H Quach","year":"2024","unstructured":"Quach H, Parmar G, Ocio EM, Prince HM, Oriol A, Crowther H, et al. A multicenter, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma. Haematologica. 2024;109:4078\u201382.","journal-title":"Haematologica"},{"key":"1436_CR17","doi-asserted-by":"publisher","first-page":"1547108","DOI":"10.3389\/fonc.2025.1547108","volume":"15","author":"N S\u00e1nchez-Avello","year":"2025","unstructured":"S\u00e1nchez-Avello N, Calvo-Pajares P, Cordero P, Suzan F, Barlas C. Subcutaneous administration of isatuximab by an on-body delivery system (OBDS) in multiple myeloma (MM) patients: results of a nurse survey. Front Oncol. 2025;15:1547108.","journal-title":"Front Oncol"},{"key":"1436_CR18","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2025.2484278","volume":"32","author":"M Desai","year":"2025","unstructured":"Desai M, Faiman B, Gorski LA, Miles A, Sterlin V, Curry N. Evaluating nurse preferences for a novel on-body delivery system vs. manual syringes for large-volume subcutaneous drug administration: a survey study. Drug Deliv. 2025;32:2484278.","journal-title":"Drug Deliv"},{"key":"1436_CR19","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","volume":"394","author":"M Attal","year":"2019","unstructured":"Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, et al. ICARIA-MM study group. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394:2096\u2013107.","journal-title":"Lancet"},{"key":"1436_CR20","doi-asserted-by":"publisher","unstructured":"Ailawadhi S, \u0160pi\u010dka I, Spencer A, Lu J, Oriol A, Ling S, et al. lsatuximab subcutaneous by on-body delivery system vs isatuximab intravenous plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma: Phase 3 IRAKLIA study. J Clin Oncol. 2025:101200JCO2500744. https:\/\/doi.org\/10.1200\/JCO-25-00744.","DOI":"10.1200\/JCO-25-00744"},{"key":"1436_CR21","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.4155\/bio.13.145","volume":"5","author":"KJ Fraley","year":"2013","unstructured":"Fraley KJ, Abberley L, Hottenstein CS, Ulicne JJ, Citerone DR, Szapacs ME. The Gyrolab\u2122 immunoassay system: a platform for automated bioanalysis and rapid sample turnaround. Bioanalysis. 2013;5:1765\u201374.","journal-title":"Bioanalysis"},{"key":"1436_CR22","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1208\/s12248-013-9552-9","volume":"16","author":"S Dudal","year":"2014","unstructured":"Dudal S, Baltrukonis D, Crisino R, Goyal MJ, Joyce A, Osterlund K, et al. Assay formats: Recommendation for best practices and harmonization from the global bioanalysis consortium harmonization team. AAPS J. 2014;16:194\u2013205.","journal-title":"AAPS J"},{"key":"1436_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jim.2015.08.002","volume":"426","author":"J Zoghbi","year":"2015","unstructured":"Zoghbi J, Xu Y, Grabert R, Theobald V, Richards S. A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays. J Immunol Methods. 2015;426:62\u20139.","journal-title":"J Immunol Methods"},{"key":"1436_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1208\/s12248-021-00649-y","volume":"24","author":"H Myler","year":"2021","unstructured":"Myler H, Pedras-Vasconcelos J, Phillips K, Hottenstein CS, Chamberlain P, Devanaryan V, et al. Anti-drug antibody validation testing and reporting harmonization. AAPS J. 2021;24:4.","journal-title":"AAPS J"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01436-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01436-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01436-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T14:24:22Z","timestamp":1768573462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01436-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,27]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1436"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01436-0","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,27]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GP: Consulting\/advisory role for Janssen and Sanofi. Honoraria from Bristol Myers Squibb and Sanofi. MC: Speaker\u2019s bureau for Amgen, Janssen, and Sanofi. FeS: no competing interests. VH: Honoraria from AbbVie, Amgen, Bristol Myers Squibb\/Celgene, Janssen, Sanofi, and Takeda; Support for attending meetings and\/or travel from Amgen, Bristol Myers Squibb\/Celgene, Janssen, and Sanofi; Participation on a Data Safety Monitoring Board or Advisory Board for Amgen, Bristol Myers Squibb\/Celgene, and Janssen. MD: Honoraria from participation in advisory boards and satellite symposia for Amgen, BeiGene, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Menarini-Stemline, Regeneron, Sanofi, and Takeda. SD: Honoraria for advisory boards and satellite symposia Amgen, AOP Pharma, Bristol Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Sanofi. JM: Consulting fees from Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, and Sanofi. Honoraria for lectures, presentations, and speaker bureaus from Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Pfizer, and Sanofi. Participation on a Data Safety Monitoring Board or advisory board for Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, and Sanofi. I\u0160: Consulting fees from Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen-Cilag, Sanofi, and Takeda. Honoraria for lectures, presentations, and speaker bureaus from Amgen, Bristol Myers Squibb, Janssen-Cilag, Sanofi, and Takeda. Support for attending meetings and\/or travel from Janssen-Cilag, Sanofi, and Takeda. Participation on a Data Safety Monitoring Board or advisory board for Amgen, Janssen-Cilag, Sanofi, and Takeda. LP, HM, GE: no competing interests. KS: Research funding from AbbVie, Beigene, Bristol Myers Squibb, Chugai, GlaxoSmithKline, Incyte, Janssen, Kyowa Kirin, Mitsubishi Tanabe, Novartis, ONO, Otsuka, Pfizer, Sanofi; Honoraria from Bristol Myers Squibb, Janssen, Pfizer, and Sanofi. JY: Research funding from AbbVie, Amgen, AstraZeneca, BrightPath Bio, Bristol Myers Squibb, Celaid Therapeutics, Chugai, Daiichi Sankyo, Genmab, Incyte, Janssen, Mitsubishi Tanabe, MSD, Novartis, Sanofi, Sumitomo Pharma, and Takeda. RH: Grants or contracts from Amgen, Bristol Myers Squibb, Celgene, Janssen, Novartis, and Takeda. Consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Janssen, Novartis, PharmaMar, and Takeda. Honoraria for lectures, presentations, and speaker bureaus: Amgen, Bristol Myers Squibb, Celgene, Janssen, PharmaMar, and Takeda. Support for attending meetings and\/or travel from Amgen, Celgene, Janssen, and Takeda. Participation on a Data Safety Monitoring Board or advisory board for Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Oncopeptides, Sanofi, and Takeda. CS, DY, PC, EC, and FS: employed by Sanofi; may hold stock and\/or stock options in the company. KB and VK: employed by Excelya on behalf of Sanofi; may hold stock and\/or stock options in the company. HQ: Research funding from Bristol Myers Squibb, GlaxoSmithKline, Karyopharm, and Sanofi; Consulting\/advisory role for Antengene, Beigene, Bristol Myers Squibb, GlaxoSmithKline, Janssen Cilag, Karyopharm, Regeneron, and Sanofi.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the local health authorities and the Institutional Review Board or Independent Ethics Committee at each study center. The study was conducted following the Declaration of Helsinki and the International Council for Harmonisation (ICH) Guidelines for Good Clinical Practice. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"16"}}